Largest biotech companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 20 biotech companies in the United States ranked by net assets, at PLN 91.7B, ahead of Biogen (PLN 73.8B) and Amgen (PLN 35B). Figures as of 19 Nov 2026, 22:39 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Gilead SciencesPLN 91.7B
- Median
- PLN 6.5B
- Combined market value
- PLN 2.97T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | PLN 91.7B | PLN 834.7B | PLN 672.99 | 1.45% down | 35% up | ||
| 2 | BiogenBIIB · Health Care | PLN 73.8B | PLN 147.6B | PLN 998.71 | 1.70% down | 49% up | ||
| 3 | AmgenAMGN · Health Care | PLN 35B | PLN 959.2B | PLN 1,773.38 | 1.14% down | 32% up | ||
| 4 | ModernaMRNA · Health Care | PLN 35B | PLN 325.9B | PLN 805.54 | 1.29% up | 780% up | ||
| 5 | Neurocrine BiosciencesNBIX · Health Care | PLN 13.1B | PLN 64.1B | PLN 632.82 | 3.85% down | 17% up | ||
| 6 | VaxcytePCVX · Health Care | PLN 10.9B | PLN 37.3B | PLN 235.85 | 0.27% down | 23% up | ||
| 7 | ExelixisEXEL · Health Care | PLN 8.7B | PLN 64.9B | PLN 266.04 | 3.60% down | 63% up | ||
| 8 | Bio-TechneTECH · Health Care | PLN 8.5B | PLN 46.2B | PLN 293.80 | 0.07% down | 24% up | ||
| 9 | RepligenRGEN · Health Care | PLN 8.5B | PLN 44B | PLN 688.18 | 1.38% down | 12% up | ||
| 10 | Revolution MedicinesRVMD · Health Care | PLN 6.6B | PLN 139.4B | PLN 644.30 | 0.24% down | 129% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | PLN 6.4B | PLN 41.2B | PLN 482.48 | 1.44% down | 87% up | ||
| 12 | Krystal BiotechKRYS · Health Care | PLN 4.9B | PLN 37.8B | PLN 1,276.31 | 0.15% up | 54% up | ||
| 13 | ImmunovantIMVT · Health Care | PLN 3.4B | PLN 27.2B | PLN 131.42 | 1.96% down | 46% up | ||
| 14 | CG OncologyCGON · Health Care | PLN 3B | PLN 29.6B | PLN 330.98 | 2.38% up | 97% up | ||
| 15 | Twist BioscienceTWST · Health Care | PLN 1.9B | PLN 30.8B | PLN 451.08 | 4.07% down | 346% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | PLN 992.1M | PLN 24.8B | PLN 203.56 | 4.94% up | 26% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | PLN 884.2M | PLN 18.3B | PLN 113.36 | 1.44% down | 74% up | ||
| 18 | Kodiak SciencesKOD · Health Care | PLN 636M | PLN 25.9B | PLN 395.64 | 0.09% up | 399% up | ||
| 19 | Halozyme TherapeuticsHALO · Health Care | PLN 197.3M | PLN 42.9B | PLN 376.00 | 2.88% down | 39% up | ||
| 20 | ImmunityBioIBRX · Health Care | -PLN 2B | PLN 28.2B | PLN 26.55 | 1.94% down | 232% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0412 PLN).
Questions and answers
Which biotech companies in the United States rank first by net assets?
Gilead Sciences (PLN 91.7B), Biogen (PLN 73.8B) and Amgen (PLN 35B) are the top three of the 20 biotech companies in the United States ranked by net assets as of 19 Nov 2026, 22:39 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by net assets.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by net assets have a combined market value of PLN 2.97T as of 19 Nov 2026, 22:39 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by net assets”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.